Curated News
By: NewsRamp Editorial Staff
November 17, 2026
MOCCI-Driven OXPHOS Rewiring Fuels Lymph Node Metastasis in Lung Cancer
TLDR
- Targeting MOCCI-driven OXPHOS in lung cancer could yield a first-in-class therapy to block lymph node metastasis and improve survival.
- MOCCI boosts oxidative phosphorylation, increasing GDF15 secretion that exhausts Tfh cells via TGFBR2 and suppresses B-cell activation.
- This research offers hope for preventing lung cancer spread by uncovering a metabolic-immune axis that could lead to therapies improving patient outcomes.
- MOCCI, a mitochondrial complex IV component, unexpectedly drives lymph node metastasis by reprogramming metabolism and suppressing local immune responses.
Impact - Why it Matters
This research uncovers a critical metabolic-immune axis that drives lymph node metastasis in lung cancer, a major cause of poor prognosis. By identifying MOCCI as a key regulator of OXPHOS reprogramming and GDF15 secretion, the study provides a potential therapeutic target to intercept metastasis. The findings also offer a rich multi-omics resource for understanding the spatial and cellular interactions within metastatic lymph nodes. For patients, this could lead to new strategies to prevent or treat lymph node metastasis, ultimately improving survival outcomes. The correlation between MOCCI expression and poorer survival underscores its clinical relevance as a prognostic biomarker and a promising avenue for drug development.
Summary
Researchers at Fudan University Shanghai Cancer Center, in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, have identified a key mechanism driving lymph node metastasis in lung cancer. The study, published in Cancer Biology & Medicine (CBM), reveals that a primary lymph node metastatic cancer cell (PLMC) subgroup, characterized by MOCCI-driven oxidative phosphorylation (OXPHOS) reprogramming, plays a pivotal role in this process. The team, led by corresponding authors Haiquan Chen, Yang Zhang, and Xiaoming Zhang, analyzed matched primary tumors, metastatic and uninvolved lymph nodes, and peripheral blood from 10 lung cancer patients using single-cell RNA sequencing and spatial transcriptomics, capturing 671,467 cells. They found that MOCCI expression correlates with OXPHOS activity, and its knockdown reduced migration and invasion by over 50% in lung cancer cells, while overexpression promoted mitochondrial respiration and lymph node metastasis in mice.
The study further uncovered that MOCCI-overexpressing cells secrete more growth differentiation factor 15 (GDF15), which acts through TGFBR2 to promote follicular helper T (Tfh) cell exhaustion and suppress neighboring B-cell activation. Spatial analyses showed that Tfh cells near GDF15-positive PLMCs had increased inhibitory signatures and reduced MHC-II signatures. In an independent cohort of 875 lung cancer cases, higher MOCCI expression was associated with lymph node metastasis and poorer overall survival in lung adenocarcinoma. The authors propose that MOCCI-mediated OXPHOS reprogramming enhances GDF15 secretion, linking metabolic adaptation to immune remodeling during cancer dissemination. They suggest that targeting MOCCI-driven OXPHOS reprogramming could be a potential strategy for intercepting lymph node metastasis and provide a valuable resource for further exploration of the cellular states and spatial interactions underlying this process. The full study can be accessed via DOI: 10.20892/j.issn.2095-3941.2025.0587.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, MOCCI-Driven OXPHOS Rewiring Fuels Lymph Node Metastasis in Lung Cancer
